ADPT - Adaptive Biotechnologies Corporation
Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.61, for a total transaction of $304,272.41. Following the sale, the chief operating officer directly owned 377,802 shares in the
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we
Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with a volume of 2895 shares trading hands. The stock had previously closed at $29.84. Analyst Ratings Changes Several research firms have commented on ADPT.
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).
Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations. Institutional and Insider Ownership 99.2% of
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $28.78 and last traded at $27.86, with a volume of 1458524 shares changing hands. The stock had previously closed at $28.61. Wall Street Analyst Weigh In Several equities research analysts
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care.
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 63.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 131,830 shares of the company's stock after selling 230,880 shares during the quarter. Algert Global LLC owned 0.08% of Adaptive
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,338 shares of the company's stock after selling 1,194,586 shares during the quarter. Dimensional
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.